Muscle modifications in fibromyalgic patients revealed by surface electromyography (SEMG) analysis by Bazzichi, Laura et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
Muscle modifications in fibromyalgic patients revealed by surface 
electromyography (SEMG) analysis
Laura Bazzichi*1, Marco Dini3, Alessandra Rossi2, Silvia Corbianco3, 
Francesca De Feo1, Camillo Giacomelli2, Cristina Zirafa1, Claudia Ferrari1, 
Bruno Rossi3 and Stefano Bombardieri1
Address: 1Department of Internal Medicine, Division of Rheumatology, S. Chiara Hospital, Pisa, Italy, 2Department of Psychiatry, Neurobiology, 
Pharmacology and Biotechnology, University of Pisa, Pisa, Italy and 3Department of Neuroscience, University of Pisa, Pisa, Italy
Email: Laura Bazzichi* - l.bazzichi@int.med.unipi.it; Marco Dini - m.dini@ao-pisa.toscana.it; Alessandra Rossi - rossi@farm.unipi.it; 
Silvia Corbianco - s.corbianco@ao-pisa.toscana.it; Francesca De Feo - fdefeo@farm.unipi.it; Camillo Giacomelli - c.giacomelli@int.med.unipi.it; 
Cristina Zirafa - cri.zirafa@tiscali.it; Claudia Ferrari - c.ferrari@gmail.com; Bruno Rossi - b.rossi@neuro.med.unipi.it; 
Stefano Bombardieri - s.bombardieri@int.med.unipi.it
* Corresponding author    
Abstract
Background: Several studies have been carried out in order to investigate surface electromyography (SEMG) response
on fibromyalgic (FM) patients. Some studies failed to demonstrate differences between FM patients and healthy individuals
while others found differences in SEMG parameters. Different muscular region have been analyzed in FM patients and
heterogeneity is also produced because of the different ways in which the SEMG technique is used.
The aims of this study were to evaluate muscle modifications by SEMG analysis in FM women with respect to a sample
of healthy controls and to investigate the relationships between SEMG parameters and the clinical aspects of the disease.
Methods: SEMG was recorded in 100 FM women (48.10 ± 11.96 yr) and in 50 healthy women (48.60 ± 11.18 yr), from
the tibialis anterior and the distal part of vastus medialis muscle during isometric contraction. Initial values and rate of
change of median spectral frequency (MDF) and conduction velocity (CV) of the SEMG signal were calculated.
The clinical parameters "Fibromyalgia Impact Questionnaire", pain, tender points, tiredness were evaluated and the
relationships between these data and the SEMG results were also studied. For the statistical analysis Mann-Whitney test,
chi-square test and Spearman correlation were used.
Results: MDF absolute values and the so-called Fatigue Index (FI) were significantly lower (p < 0.001) in both muscles
studied in FM patients (MDF: 93.2 μV; FI: 1.10, 0.89) with respect to healthy controls (MDF: 138.2 μV; FI: 2.41, 1.66) and
a smaller reduction in the percentage values of MDF was observed in FM patients vs controls (22% vs 38%). A significant
correlation was found between the SEMG parameter decrement of normalized median frequency (MNF) (%) and
seriousness of FM (evaluated by means of tender points).
Conclusion: We have found some interesting muscle modifications in FM patients with respect to healthy controls,
regarding MDF, CV and FI values which resulted significantly lower in FM. Patients might have a different fiber recruitment
or a possible atrophy of type II fibers suggesting that they are not able to reach muscle relaxation.
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Background
Surface Electromyography (SEMG) is a non-invasive tech-
nique which can provide useful information regarding a
muscle's functional status. The use of SEMG has become
widespread because of its non-invasive characteristic (dif-
ferently from classic EMG, it is needle free) and for the
potentiality to explore muscle fibre type characteristics; in
fact this method has been applied in the estimation of
muscle fatigue phenomena, monitoring the physiological
effects of rehabilitation and training [1-6].
Fibromyalgia (FM) is a chronic disorder characterized by
widespread musculoskeletal pain and fatigue [7]. Patients
with FM display low pain threshold levels at specific ana-
tomic areas called tender points [8]. Most FM patients
report disrupted or non-restorative sleep, mood distur-
bances, and several more syndromes (e.g., restless leg syn-
drome, irritable bowel syndrome and chronic headaches)
[9,10], consequently physical and emotional health as
well as quality of life is often seriously impaired [11,12].
For the peculiar characteristics of SEMG, it can be consid-
ered a useful technique in assessing the muscle status of
FM patients and for analyzing some aspects of their
peripheral fatigue. Conduction velocity (CV) and median
frequency (MDF) are the two parameters measured by
SEMG. Because they have been shown to be indirect meas-
urements of the diameter of muscle fibers and indirect
means for inferring the fiber type muscle constitution,
SEMG may be used to assess the modifications of FM mus-
cle.
A heterogeneous picture exists in literature about SEMG
and EMG studies on FM patients, some studies failed to
demonstrate differences between FM and healthy individ-
uals [13-16], while others found differences in CV values
and/or in other parameters [17-22]. Different muscular
region have been analyzed in FM patients, furthermore
heterogeneity is produced because of the different ways in
which the SEMG technique is used.
In light of these results, we propose to assess the muscular
response detected by SEMG at tibialis anterior and the dis-
tal part of vastus medialis muscle in a large cohort of FM
patients, to compare the results with a sample of healthy
controls, and to investigate the relationships between
their muscle modifications and clinical aspects of the dis-
ease.
Methods
Subjects
100 consecutive women affected by primary fibromyalgia,
aged 48.10 ± 11.96 yr (mean age ± S.D.), and 50 healthy
women (48.60 ± 11.18 yr) were enrolled. Patients were
recruited and clinically classified at the Division of Rheu-
matology, University of Pisa (S. Chiara Hospital) accord-
ing to the 1990 American College of Rheumatology
criteria (ACR criteria) [1], which include: pain for more
than 3 months from all of the four body quadrants, axial
skeletal pain and pain upon digital palpation of at least 11
out of 18 specific bilateral points. The healthy controls
were either friends or neighbours of patients. Controls
were allowed to report sporadic or situation-related minor
headache and/or muscle aches because of the universal
nature of such symptoms.
Exclusionary criteria for normal volunteers were: any of
the above ACR criteria for fibromyalgia; use of any medi-
cation. Exclusionary criteria for patients were: the pres-
ence of a major clinical condition other than
fibromyalgia. Were excluded from the study patients and
controls with recent or past history of psychiatric disor-
ders, neuromuscular pathology, metabolic and endo-
crinological disorders, kidney, hepatic and heart failure
and pregnant females.
Patients and controls had comparable body mass index
(BMI) and nobody of them was obese (data not shown).
All the participants answered a questionnaire about phys-
ical activity, they resulted employed in half-time jobs or at
home with small children for less than 4 h per day.
SEMG analyses were performed at the Unit of Neuroreha-
bilitation, at the S. Chiara Hospital (Pisa).
Written consent was obtained from all patients and con-
trols after a full explanation of the procedure.
Evaluation of clinical parameters
Tenderness at tender points was evaluated in each subject
using the Fischer dolorimeter [23]. A rheumatologist
applied the instrument at a rate of 1 Kg/s and the patient
was instructed to say when this procedure became painful.
The pain threshold was calculated for 18 points, and the
tender point (TP) count was determined by the number of
tender points that had a threshold of ≤ 4 kg/cm2. The total
fibromyalgic tender point score (right + left) was used in
the statistical analysis.
Either patients or controls received a "Fibromyalgia
Impact Questionnaire" (FIQ) containing 10 different
items, each of them being evaluated to gave the FIQ total
score [24]. Total score reflect the impact of fibromyalgia
on quality of life, ranging from 0 (no impact) to 100
(maximum impact). For each patient an evaluation was
also made of fatigue, stiffness and pain by means of a vis-
ual analogic scale (VAS).
Myoelectric measurement and experimental procedure
The tibialis anterior and the distal part of vastus medialis
muscle were selected for this study because of the rela-
tively extensive body of data available on its structure andBMC Musculoskeletal Disorders 2009, 10:36 http://www.biomedcentral.com/1471-2474/10/36
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behaviour particularly suitable for conduction velocity
(CV) measurements [25].
Patients and controls were examined lying on a bed with
an articular angle of 135° for vastus medialis obliquus
muscle and of 110° for tibialis anterior.
The force of the ankle dorsiflexion was recorded with an
electronic strain gauge inserted in a specially foot isomet-
ric ergometer.
The motor point of the muscle were found by means of
electrical stimulation and that point, with the lowest stim-
ulation threshold providing the highest muscle contrac-
tion, visually registered, was chosen for the stimulation
protocol. Stimulation consisted of pulse trains (each stim-
ulus 0.3 msec in width) delivered at a frequency of 15 Hz
and 35 Hz; the 15 Hz value is near the threshold for fused
contraction while 35 Hz represents the highest frequency
without M-waves overlapping.
A supramaximal stimulation 10–15% above the level gen-
erating the maximum amplitude motor-evoked potential
was applied. The myoelectric signal was detected with the
4 bar electrode technique described by Broman et al. [26].
A single differential output was obtained from the 2 cen-
tral bars and was used to compute the median spectral fre-
quency (MDF). The detection technique provided 2
double-differential outputs from which the muscle fibre
CV was estimated [26].
The electrode was moved over the muscle in the area
between the most distal motor point and the tendon and
then fixed with an elastic strap in a position that showed
highly correlated double differential signals during the
stimulations, according to Roy et al. [25].
When the detection electrode was applied correctly, and
after a 5 min rest so that the subject did not feel any
fatigue effect, stimulated contractions lasting 30 s were
performed with the subject relaxed and physically passive;
the absence of voluntary myoelectric signals (ME) signals
indicated this state. For each subject two supramaximal
isometric electrically elicited contractions, lasting 30 sec-
onds, were evoked at the frequency of 15 Hz and 35 Hz,
and a 10 min interval was allowed for recovery between
contractions.
The stimulation artefact, which detrimentally affects the
myoelectric signal, was suppressed electronically by
means of a technique described by Knaflitz and Merletti
[27].
CV and MDF rate of change (m/s2 and Hz/s respectively)
and their normalized values (%/s) were calculated.
The laboratory personnel were blinded as to the diagnosis
(healthy control or FM) of the subjects, and the subjects
were instructed not to disclose their diagnostic status. All
the data processed before the statistical analysis was made
without knowledge of the diagnostic status of the subjects.
Data management
The Median Spectral Frequency (MDF, Hz) and Conduc-
tion Velocity (CV, m/s) were computed off-line with
numerical algorithms according to the methods described
by McGill and Dorfman [28] and Merletti et al. [29],
respectively, then tabulated and plotted versus time for
each stimulated contraction.
The MDF and the CV data values collected from FM sub-
jects and controls showed a curvilinear trend over time,
which could be modelled with a polynomial curve of type
y = at2 + bt + c.
A normalized fatigue index (FI) as 100b/c, was defined,
where: b is the value of the slope of the polynomial curve
for t = 0, and c is the initial value [30].
Statistical analysis
A polynomial curve was applied to the data to calculate
the initial value and rate of change of MDF and CV. The
polynomial curve model was shown to fit the experimen-
tal data better than the exponential model. The normal-
ized rate of change for each variable was calculated as the
percentage ratio between rate of change and initial value.
For the statistical analysis of the data, Mann-Whitney test, chi-
square test and Spearman correlation were used. Two-tailed p
values less than 0.05 were considered to be significant.
Results
Background variables of FM patients and controls are
shown in Table 1.
Regarding SEMG results only the results of the frequency
of 35 Hz are shown. In Tab. 2 are shown the mean ± SD
of MDF, CV and FI values calculated on all patients and
controls at time 0 (t = 0, basal) and after 30 secs (t = 30);
there are significant differences between the mean MDF
absolute values at basal (time = 0) (93.2 ± 6.0 μV vs 138.2
± 5.1 μV) and the so-called Fatigue Index (FI, 1.10 vs 2.41;
0.89 vs 1.66), which all resulted significantly lower (P <
0.0001) in fibromyalgic patients with respect to controls.
Figs. 1 and 2 show the typical response of SEMG (MDF
and CV respectively, normalized values) in 100 FM
patients and in 50 controls, at the frequency of 35 Hz.
A significant smaller reduction (p < 0.001) of MDF (%)
and CV (%) was found in FM patients with respect to con-
trols.BMC Musculoskeletal Disorders 2009, 10:36 http://www.biomedcentral.com/1471-2474/10/36
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The response of SEMG at the frequency of 15 Hz is not
shown because there was no statistically significant differ-
ence between FM patients and the control group at this
stimulation frequency.
A significant and negative correlation was found in FM
patients between the % of MDF decrement and the
number of TPs (r = -0.44, P = 0.0001). Non-significant
correlations were found between the SEMG parameters FI,
%MDF, %CV and age, duration of disease, FIQ, fatigue,
pain and stiffness.
Discussion
In our study a different muscular response detected by
means of SEMG at the tibialis anterior and the distal part
of vastus medialis muscle has been demonstrated in
patients affected by fibromyalgia. FM patients exhibited
lower MDF and CV absolute values with respect to healthy
controls and the main difference revealed involves the rate
of CV and MDF change during stimulated contraction,
which was lower in FM patients. A smaller reduction in
their percentage values was observed in FM patients with
respect to controls (22% vs 38%). In particular, FM
patients sustained an apparent smaller fatigue related
decrease in both MDF and CV values compared to con-
trols, which let us suppose muscle modifications in FM
patients. Also Fatigue Index values resulted significantly
lower in FM.
In normal subjects the CV values decrease during pro-
longed contraction and this is an electrical manifestation of
fatigue [31]. The decrease, is proportional to the ratio of
type I/type II fibres; that is, the greater the number of type
II fibres, the greater the decrement. This provides us with
information about the fibre-type distribution. MDF is influ-
enced by muscle fibre diameter and fatigue phenomena
and is generally accepted as one of the power spectrum
parameters most suitable for tracking spectral compression
due to localized muscle fatigue [32] and MDF modifica-
tions during stimulated contraction are strictly related to
reductions in CV [31]. In the light of the above mentioned
notions, we may suppose the existence of muscle modifica-
tions in fibromyalgic patients, in particular of type II fibers,
the white rapidly contracting type fibers.
Several studies that investigated SEMG activity failed to
demonstrate differences between FM patients and healthy
controls [13-16,33]. Other papers reported a difference
between values of CV and/or in other parameters of SEMG
activity during isometric exercise in patients with FM and
healthy controls [17-22]. Furthermore in literature is
present a great heterogeneity about the SEMG technique
applied, however our results are in accordance with earlier
findings that patients with chronic pain have increased
muscle tension.
The parameters % MDF decrement correlated significantly
and negatively with the number of TPs, linking a clinical
index with an instrumental measure of muscle modifica-
tion. That is, when patients feel worse, we may suppose a
smaller recruitment or an atrophy of type II fibres.
Table 1: Background variables of FM patients (N = 100) and 
controls (N = 50). (Values are expressed as mean ± SD).
FM Controls
Age (years) 48.10 ± 11.96 48.60 ± 11.18
Duration of disease (years) 6.04 ± 6.12 -
FIQ 60.95 ± 17.48 8.50 ± 5.72
TP 15.49 ± 4.33 2.75 ± 1.80
Fatigue 7.15 ± 2.46 0.25 ± 0.40
Pain 7.01 ± 2.46 0
Stiffness 6.95 ± 2.45 1.60 ± 2.10
FIQ: Fibromyalgia Impact Questionnaire; TP: tender point.
Table 2: Absolute basal (t = 0 secs) and final values (t = 30 secs) (mean ± SD) of MDF, CV and FI of FM patients and controls.
MDF (μV)
FM
CV (m/sec)
FM
MDF (μV)
controls
CV (m/sec)
controls
Basal (t = 0 secs) 93.2* ± 6.0 4.0 ± 0.5 138.2* ± 5.1 5.1 ± 0.5
Final (t = 30 secs) 72.6 ± 3.9 3.1 ± 0.3 86.1 ± 2 3.4 ± 0.3
Fatigue Index 1.10* 0.89* 2.41* 1.66*
MDF: median spectral frequency; CV: conduction velocity
MDF and CV are expressed as absolute values. Mean ± SD of MDF, CV and FI are calculated
on 100 patients and 50 controls.
*Basal MDF controls vs basal MDF FM, p < 0.0001
*Fatigue Index controls (MDF and CV) vs Fatigue Index FM (MDF and CV), p < 0.0001BMC Musculoskeletal Disorders 2009, 10:36 http://www.biomedcentral.com/1471-2474/10/36
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In a previous research, one of us examined the muscle
changes occurring in Parkinson's disease (PD) [34] and
found that the main difference observed between PD sub-
jects and controls was the rate of change of MDF and CV
during the course of stimulated contraction; patients with
PD, like FM patients, sustained a smaller fatigue related
decrease in both parameters compared to controls. Fur-
thermore muscle biopsy of patients with PD was per-
formed in this study and histological data showed a
tendency towards hypertrophy of red type I fibres, rich in
oxidative enzymes, and atrophy of type II fibres. The mus-
cle changes occurring in Parkinson's disease have been
hypothesized as a consequence of the modified pattern of
motor unit activation and rigidity, which are characteristic
of the disease. FM and PD disease are different in many
aspects, and it is not easy to explain, but our SEMG results
showed similar muscular response, which let us suppose
a similar metabolic state.
In the late 1980s several studies regarding muscle biopsies
of FM patients were carried out. Atrophy of type II fibres
has been reported in several studies and in different mus-
cular regions [35-37]; studies of the normal trapezius
muscle indicate a relatively poor supply of capillaries as
well as low mitochondrial volume density compared to
limb muscles [38]. From this point of view we may
hypothesize that the problems of FM patients might be
due to a consequence of the modified pattern of motor
unit innervation. FM patients show an activation pattern
similar to PD patients, with a possible atrophy of type II
fibres. In this context, paradoxically, anaerobic exercise
would seem useful in muscular rehabilitation of FM
patients.
In accordance with this hypothesis, recent studies support
the hypothesis of a dysfunction of dopaminergic neuro-
transmission in fibromyalgic patients [39] and indicate
that it represents an important relevant target for the treat-
ment of fibromyalgia. Dopamine is best known for its role
in pleasure, motivation and motor control and in the
basal ganglia it may also be important for pain modula-
tion, where it can be released in response to noxious stim-
ulation and leads to endogenous antinociception.
Dopaminergic agonists of receptors D3/2 have been effi-
cacious in decreasing the symptoms of fibromyalgia; Hol-
man [40], Holman and Myers [41], in a pilot double
blinded study, reported a decrease of pain evaluated by
visual analogic scale (VAS) and improvement in other
parameters such as rigidity and myalgic score of TPs after
the treatment with ropinirole and pramipexole.
Normalized values of MDF in FM patients and controls (0–30 sec) Figure 1
Normalized values of MDF in FM patients and controls (0–30 sec).BMC Musculoskeletal Disorders 2009, 10:36 http://www.biomedcentral.com/1471-2474/10/36
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Conclusion
A heterogeneous literature exists about the matter if
chronic pain conditions are associated with changes in
CV, firing rate, measured by SEMG. In the present study of
severe chronic pain condition like fibromyalgia and
healthy controls, we have found some interesting muscle
modifications in FM patients with respect to healthy con-
trols, regarding MDF, CV and FI values which resulted sig-
nificantly lower in FM. In particular it seems that FM
patients show an activation pattern of motor unit similar
to that of patients affected by PD disease, with a possible
atrophy of type II fibers.
SEMG, which is a non invasive technique and needle free,
from this point of view might be useful in assessing the
modifications of muscle characteristics in FM patients and
it might be an instrument to support diagnosis, to individ-
uate target therapies and to evaluate disease evolution and
improvement during a period of time.
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